News for Healthier Living
Moffitt Consortium Study Answers Questions About Long-Term Survivorship Following CAR T Treatment
Axicabtagene ciloleucel, commonly known as axi-cel, is an innovative immunotherapy that uses modified T cells to target and destroy cancer cells. Approved for patients who have not responded to at least two prior lines of therapy, axicabtagene ciloleucel has been a game-changer in treating large B-cell lymphoma.
August 5, 2024
September 10 2024September 9 2024September 8 2024September 7 2024September 6 2024September 5 2024September 4 2024September 3 2024September 2 2024September 1 2024August 31 2024August 30 2024August 29 2024August 28 2024
|
|
|
|
|